Compare Allstate Corp (ALL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs Mesoblast Limited — how do they compare? Allstate Corp trades at $262.54 (market cap $68.19B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Allstate Corp is far larger — about 31.6× Mesoblast Limited's market cap, and Allstate Corp pays a 1.6% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| ALL | MESO | |
|---|---|---|
Market Cap | $68.19B | $2.16B |
Sector | Financials | Technology |
52-Week High | $275.11 | $20.96 |
52-Week Low | $190.00 | $12.88 |
Enterprise Value | $76.84B | $2.17B |
Dividend Yield | 1.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $267.00, down 2.95% on the day, but maintains a bullish technical signal with strong fundamental momentum. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, and has consistently exceeded expectations in recent quarters. Revenue growth is steady, with 2025 revenue at $67.07 billion and net income margin improving to 19.19%. The stock is attractively valued with a P/E of 5.35 and offers a dividend, with recent payouts of $1.08 per share.
The outlook for ALL is positive, driven by strong underwriting performance and earnings beats, though sustainability of peak profitability is a concern. Investment opportunity lies in its low valuation and dividend yield, but risks include potential normalization of underwriting results and competitive pressures. Analyst consensus is mixed with a $266.54 price target, indicating limited near-term upside from current levels.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
